Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

The development of new treatments for older patients with acute myeloid leukemia is an active area, but has met with limited success. Vosaroxin, a quinolone-derived intercalating agent has several properties that could prove beneficial. Initial clinical studies showed it to be well-tolerated in olde...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Dennis, Mike, Russell, Nigel, Hills, Robert K., Hemmaway, Claire, Panoskaltsis, Nicki, McMullin, Mary-Frances, Kjeldsen, Lars, Dignum, Helen, Thomas, Ian F., Clark, Richard E., Milligan, Don, Burnett, Alan K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2015
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4536889/
https://ncbi.nlm.nih.gov/pubmed/25805811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-608117
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge